Evaluating a protein as a marker for liver cancer recurrence
Recurrent Liver Cancer: Reconceptualization and Reevaluation
This study is trying to see if higher levels of a certain protein in the blood can help predict if liver cancer will come back in people who have already had it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06430983 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine if elevated levels of a specific protein can indicate the recurrence of liver cancer. It will compare 50 recurrent liver cancer patients with 250 additional recurrent liver cancer patients to assess the protein's levels against those of primary liver cancer patients. The study will collect clinical data, including demographics and medical history, while implementing strict quality control measures to ensure data reliability. Participants will provide blood samples for analysis, and the study has received ethical approval.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with recurrent or primary liver cancer who can provide informed consent and blood samples.
Not a fit: Patients who are pregnant, have received organ transplants, or have other tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for the early detection of liver cancer recurrence, improving patient monitoring and outcomes.
How similar studies have performed: While the approach of using biomarkers for cancer recurrence is common, the specific protein being evaluated in this study may represent a novel focus that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with primary hepatocellular carcinoma or diagnosed with non-HCC * The patient or the patient's legal representative must be able to read, understand, and sign the informed consent form * Agree to provide blood samples and have good clinical compliance * Complete clinical basic information, including: the patient's unique traceability number (ID card number/outpatient number/health insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver disease), imaging examination confirmed heteromorphic liver cancer (for non-HCC patients) Exclusion Criteria: * Pregnant women * Those who have received organ transplantation * Non-HCC patients diagnosed with other tumors * Patients with primary hepatocellular carcinoma complicated by other tumors * Those judged by the researcher as not meeting the inclusion criteria
Where this trial is running
Nanjing, Jiangsu
- The Second Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: zhang yewei, doctor
- Email: zhangyewei@njmu.edu.cn
- Phone: +86 13813885788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.